News Column

GliaCure Appoints New Member to Board of Directors

August 4, 2014



By a News Reporter-Staff News Editor at Pharma Business Week -- GliaCure, Inc., a company focused on developing novel, non-neuronal therapies for a range of neurological and neuropsychiatric disorders, announced that it has appointed Joseph S. Zakrzewski to the Company's Board of Directors (see also GliaCure, Inc.).

Mr. Zakrzewksi brings more than 20 years of experience to his new role as a director of GliaCure. He has held various executive positions in the biotechnology and pharmaceutical industry and has served on the Board of Directors of publicly held companies Acceleron Pharmaceuticals, Amarin Pharmaceuticals, Insulet Corporation, and Liposcience. He also currently serves on the board of a number of privately held companies, and is advisor to a number of entities. He was most recently Chairman and CEO of Amarin Pharmaceuticals.

"We are exceptionally fortunate to have Joe Zakrzewksi join our team," said Phil Haydon, Ph.D., President and co-Founder of GliaCure. "His wealth of experience in developing life sciences companies will clearly bring a new depth and dynamism to GliaCure and help us reach a new level."

"Major pharma companies increasingly talk about embracing 'disruptive thinking,'" Mr. Zakrzewski said. "With its novel focus on non-neuronal pathways, its ability to make quick decisions, and its virtual approach, GliaCure epitomizes this disruptive thinking. I welcome the opportunity to become part of such an exciting company."

Prior to his time as an executive and board member at Amarin Pharmaceuticals Mr. Zakrzewski served as a Venture Partner with Orbimed, the world's largest healthcare-dedicated investment firm. He has also served as Chairman, President & Chief Executive Officer of Xcellerex, as the Chief Operating Officer of Reliant Pharmaceuticals, and held a variety of executive level positions at Eli Lilly & Company including the position of Vice President, Corporate Business Development. Mr. Zakrzewski received an MS in Biochemical Engineering from Drexel University and an MBA in Finance from Indiana University.

Keywords for this news article include: GliaCure Inc.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Pharma Business Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters